What Veracyte, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 10 | 58 |
| Total trades | 16 | 119 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 959,794 |
| Disposed | 57,320 | 687,752 |
| Net activity | −57,320 | +272,042 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Bhanji Muna | Director | Oct 19 | Open-market sale · S | −1,864 | $43.70 | −$81.5K | 40,854 |
| Leite John | Global Chief Commercial Off | Sep 21 | Open-market sale · S | −4,015 | $40.00 | −$161K | 124,329 |
| Holstein Jens | Director | Sep 14 | Open-market sale · S | −5,000 | $40.95 | −$205K | 27,471 |
| McGuire Annie | EVP, General Counsel | Sep 04 | Open-market sale · S | −1,100 | $43.67 | −$48K | 131,160 |
| McGuire Annie | EVP, General Counsel | Sep 04 | Open-market sale · S | −2,154 | $42.79 | −$92.2K | 132,260 |
| Chambers Rebecca | Chief Financial Officer | Sep 04 | Open-market sale · S | −1,175 | $43.71 | −$51.4K | 166,025 |
| Chambers Rebecca | Chief Financial Officer | Sep 04 | Open-market sale · S | −2,477 | $42.81 | −$106K | 167,200 |
| Febbo Phillip G. | Chief Scientific & Med Officer | Sep 04 | Open-market sale · S | −2,705 | $43.66 | −$118K | 133,048 |
| Febbo Phillip G. | Chief Scientific & Med Officer | Sep 04 | Open-market sale · S | −10,405 | $42.89 | −$446K | 135,753 |
| Wygant Jonathan | VP, Chief Accounting Officer | Sep 02 | Withheld — tax / exercise cost · F | −1,361 | $44.88 | −$61.1K | 43,226 |
| McGuire Annie | EVP, General Counsel | Sep 02 | Withheld — tax / exercise cost · F | −3,215 | $44.88 | −$144K | 134,414 |
| Stapley Marc | Chief Executive Officer | Sep 02 | Withheld — tax / exercise cost · F | −8,782 | $44.88 | −$394K | 432,073 |
| Chambers Rebecca | Chief Financial Officer | Sep 02 | Withheld — tax / exercise cost · F | −3,603 | $44.88 | −$162K | 169,677 |
| Febbo Phillip G. | Chief Scientific & Med Officer | Sep 02 | Withheld — tax / exercise cost · F | −3,639 | $44.88 | −$163K | 146,158 |
| Leite John | Global Chief Commercial Off | Sep 02 | Withheld — tax / exercise cost · F | −3,961 | $44.88 | −$178K | 128,344 |
| Bhanji Muna | Director | Sep 01 | Open-market sale · S | −1,864 | $42.97 | −$80.1K | 42,718 |
| Eastham Karin | Director | Jun 18 | Open-market sale · S | −529 | $53.55 | −$28.3K | 15,097 |
| Eastham Karin | Director | Jun 18 | Open-market sale · S | −3,200 | $52.78 | −$169K | 15,626 |
| Shafer David Brent | Director | Jun 11 | Grant / award · A | +5,272 | — | — | 31,100 |
| Barr Eliav | Director | Jun 11 | Grant / award · A | +5,272 | — | — | 56,461 |
Loading...